BIO-PATH HOLDINGS INC by Bio-Path Holdings, Inc. Analyst Price Targets - Benzinga

SPY763.13−1.12%QQQ709.85−2.49%BTC/USD81,568.71−0.68%DIA518.70−0.45%GLD381.90−0.21%TLT80.04+0.09%

BIO-PATH HOLDINGS INC by Bio-Path Holdings, Inc.

BPTHOTCEM

Trade with Public

Trade with Public

$0.00030

-0.21-99.86%

Last update: Oct 15, 3:06 PM

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

BIO-PATH HOLDINGS INC by Bio-Path Holdings, Inc. Analyst Price Targets

Wall Street analyst price targets and consensus rating for BIO-PATH HOLDINGS INC by Bio-Path Holdings, Inc. (BPTH).

Price Target Range — 3 Quarters

Analyst Consensus — 1 Analysts

1Buy

Consensus RatingBuy# Analysts1Avg. Consensus PT$30Upside to Avg. PT+9999900.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jul 8, 2024	Roth MKM	Philip Shen	Maintained	Buy	$20
Apr 18, 2024	Roth MKM	Philip Shen	Maintained	Buy	$40
Mar 27, 2024	Roth MKM	Jonathan Aschoff	PT Raise	Buy	$12→$40

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Roth MKM Reiterates Buy on Bio-Path Hldgs, Maintains $20 Price Target

Roth MKM analyst Philip Shen reiterates Bio-Path Hldgs (NASDAQ:BPTH) with a Buy and maintains $20 price target.

Benzinga Newsdesk

PRO
Roth MKM Reiterates Buy on Bio-Path Hldgs, Maintains $40 Price Target

Roth MKM analyst Philip Shen reiterates Bio-Path Hldgs (NASDAQ:BPTH) with a Buy and maintains $40 price target.

Benzinga Newsdesk

10 Biggest Price Target Changes For Thursday

Telsey Advisory Group cut the price target for Bath & Body Works, Inc. (NYSE: BBWI) from $70 to $60. Bath & Body Works shares fell 6.9% to $40.00 in pre-market trading.

Lisa Levin

PRO
HC Wainwright & Co. Maintains Buy on Bio-Path Holdings, Lowers Price Target to $9

HC Wainwright & Co. analyst Yi Chen maintains Bio-Path Holdings (NASDAQ:BPTH) with a Buy and lowers the price target from $12 to $9.

Benzinga Newsdesk

Benzinga's Top Ratings Upgrades, Downgrades For March 11, 2021

Benzinga Insights

PRO
Roth Capital Initiates Coverage On Bio-Path Holdings with Buy Rating, Announces Price Target of $13

Roth Capital analyst Jonathan Aschoff initiates coverage on Bio-Path Holdings (NASDAQ:BPTH) with a Buy rating and announces Price Target of $13.

Benzinga Newsdesk